Literature DB >> 9303515

Effects of interferon treatment on the antiviral T-cell response in hepatitis C virus genotype 1b- and genotype 2c-infected patients.

G Missale1, E Cariani, V Lamonaca, A Ravaggi, A Rossini, R Bertoni, M Houghton, Y Matsuura, T Miyamura, F Fiaccadori, C Ferrari.   

Abstract

The viral genotype may influence the response to interferon (IFN) treatment in chronic hepatitis C virus (HCV) infection. To characterize potential mechanisms responsible for this effect, we assessed whether IFN modulation of HCV-specific T-cell responses differs in patients infected by different genotypes. The T-cell response to HCV core protein was sequentially analyzed before and during IFN treatment in two groups of patients chronically infected with HCV genotype 1b (eight patients) or 2c (eight patients). Overlapping 20 mer peptides corresponding to the amino acid sequence of the prevalent viral population identified in the serum of each patient were used for the analysis of the T-cell proliferative response to avoid possible problems caused by amino acid differences between infecting virus and HCV proteins used in vitro. Recombinant HCV core antigen was used in parallel. The level of viremia was monitored by competitive polymerase chain reaction (PCR). The T-cell response to HCV peptides and recombinant core protein detected throughout the follow-up was significantly more vigorous in genotype 2c- than in genotype 1b-infected patients. This difference was the result of a greater enhancement of the T-cell response caused by IFN treatment in genotype 2c- compared with genotype 1b-infected patients. The different IFN modulatory effect on T cells from genotype 1b- and genotype 2c-infected patients illustrates an aspect of the virus-host interaction, which may contribute toward the explanation of why different genotypes differ in responsiveness to IFN treatment.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9303515     DOI: 10.1053/jhep.1997.v26.pm0009303515

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  11 in total

1.  Relationships between cellular immune responses and treatment outcomes with interferon and ribavirin in HIV/hepatitis C virus co-infection.

Authors:  Camilla S Graham; Annalee Wells; Tun Liu; Kenneth E Sherman; Marion Peters; Raymond T Chung; Atul K Bhan; Janet Andersen; Margaret James Koziel
Journal:  AIDS       Date:  2006-02-14       Impact factor: 4.177

2.  Response of combination therapy on viral load and disease severity in chronic hepatitis C.

Authors:  Deepak Kumar; Abdul Malik; Mohammad Asim; Anita Chakravarti; Rakha H Das; Premashis Kar
Journal:  Dig Dis Sci       Date:  2007-10-13       Impact factor: 3.199

3.  Compartmentalization of hepatitis C virus quasispecies in blood mononuclear cells of patients with mixed cryoglobulinemic syndrome.

Authors:  Gianguglielmo Zehender; Chiara De Maddalena; Flavia Bernini; Erika Ebranati; Giuseppe Monti; Piero Pioltelli; Massimo Galli
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

4.  Genetic heterogeneity of hypervariable region 1 of the hepatitis C virus (HCV) genome and sensitivity of HCV to alpha interferon therapy.

Authors:  K Sandres; M Dubois; C Pasquier; J L Payen; L Alric; M Duffaut; J P Vinel; J P Pascal; J Puel; J Izopet
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

5.  Plasmacytoid dendritic cells are productively infected and activated through TLR-7 early after arenavirus infection.

Authors:  Mónica Macal; Gavin M Lewis; Stefan Kunz; Richard Flavell; James A Harker; Elina I Zúñiga
Journal:  Cell Host Microbe       Date:  2012-06-14       Impact factor: 21.023

6.  Strain-specific T-cell suppression and protective immunity in patients with chronic hepatitis C virus infection.

Authors:  Kazushi Sugimoto; David E Kaplan; Fusao Ikeda; Jin Ding; Jonathan Schwartz; Frederick A Nunes; Harvey J Alter; Kyong-Mi Chang
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

7.  Peripheral virus-specific T-cell interleukin-10 responses develop early in acute hepatitis C infection and become dominant in chronic hepatitis.

Authors:  David E Kaplan; Fusao Ikeda; Yun Li; Nobuhiro Nakamoto; Sutharsan Ganesan; Mary E Valiga; Frederick A Nunes; K Rajender Reddy; Kyong-Mi Chang
Journal:  J Hepatol       Date:  2008-03-07       Impact factor: 25.083

8.  Impact of oral silymarin on virus- and non-virus-specific T-cell responses in chronic hepatitis C infection.

Authors:  O Adeyemo; H Doi; K Rajender Reddy; D E Kaplan
Journal:  J Viral Hepat       Date:  2013-04-12       Impact factor: 3.728

9.  Antigen-specific T lymphocyte proliferation decreases over time in advanced chronic hepatitis C.

Authors:  C Morishima; A M Di Bisceglie; A L Rothman; H L Bonkovsky; K L Lindsay; W M Lee; M J Koziel; R J Fontana; H-Y Kim; E C Wright
Journal:  J Viral Hepat       Date:  2011-12-16       Impact factor: 3.728

10.  Therapeutic DNA vaccination using in vivo electroporation followed by standard of care therapy in patients with genotype 1 chronic hepatitis C.

Authors:  Ola Weiland; Gustaf Ahlén; Helmut Diepolder; Maria-Christina Jung; Sepideh Levander; Michael Fons; Iacob Mathiesen; Niranjan Y Sardesai; Anders Vahlne; Lars Frelin; Matti Sällberg
Journal:  Mol Ther       Date:  2013-06-11       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.